Cargando…
Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?
PURPOSE: To evaluate the use of high-dose radiotherapy using carbon ions (C12) on non-adenoid cystic malignant salivary gland tumors (MSGT). PATIENTS AND METHODS: Between 2009 and 2013, patients with biopsy-proven non-ACC MSGT histologies of the head and neck received a combined regimen of IMRT plus...
Autores principales: | Jensen, A. D., Poulakis, M., Vanoni, V., Uhl, M., Chaudhri, N., Federspil, P. A., Freier, K., Krauss, J., Debus, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936021/ https://www.ncbi.nlm.nih.gov/pubmed/27386864 http://dx.doi.org/10.1186/s13014-016-0657-z |
Ejemplares similares
-
An Update on Grading of Salivary Gland Carcinomas
por: Seethala, Raja R.
Publicado: (2009) -
Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck
por: Jensen, A D, et al.
Publicado: (2019) -
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Jensen, Alexandra D, et al.
Publicado: (2011) -
“Dedifferentiation” and High-Grade Transformation in Salivary Gland Carcinomas
por: Nagao, Toshitaka
Publicado: (2013) -
Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC
por: Brayer, Kathryn J., et al.
Publicado: (2023)